{"id":"W4293280727","doi":"10.1093/ckj/sfac189","title":"SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence","year":2022,"lang":"en","type":"review","venue":"Clinical Kidney Journal","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Vifor Pharma; GlaxoSmithKline Australia; Kyowa Kirin Pharmaceutical Development; Idorsia Pharmaceuticals; Amicus Therapeutics; Novo Nordisk; AstraZeneca; Chiesi Farmaceutici; Menarini Group; Astellas Pharma US; Alexion Pharmaceuticals; Fresenius Medical Care North America; Bayer; Amgen","keywords":"Proteinuria; Albuminuria; Medicine; Nephrotic syndrome; Kidney disease; Randomized controlled trial; Internal medicine; Glycemic; Diabetes mellitus; Urology; Intensive care medicine; Kidney; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001513141,0.0008430564,0.002912398,0.002543728,0.0002290852,0.001420143,0.001071001,0.001177517,0.005010249],"category_scores_gemma":[0.002844702,0.0003157372,0.001781727,0.003020201,0.0003291345,0.001119331,0.0006742741,0.001536061,0.0008007258],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005686523,"about_ca_system_score_gemma":0.001759285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001311132,"about_ca_topic_score_gemma":0.003283259,"domain_scores_codex":[0.9995446,0.0001094005,0.0001136233,0.00005982668,0.0001396159,0.00003285436],"domain_scores_gemma":[0.9984102,0.001039055,0.0002274488,0.00002238618,0.0002477374,0.00005323309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002300977,0.0000545217,0.0002251751,0.1977624,0.0008526612,0.0001530111,0.00008433058,0.00020849,0.0004891264,0.001252798,0.02132612,0.7773613],"study_design_scores_gemma":[0.0002197228,0.0003166933,0.002897074,0.1703369,0.005760031,0.001801182,0.00018806,0.0002001089,0.0004068645,0.002446004,0.8153869,0.00004039133],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005094926,0.9995772,0.0000193065,0.0001190485,0.00005833428,0.000003537808,0.00001008367,0.000001884132,0.0001595616],"genre_scores_gemma":[0.0003425822,0.9993858,0.00005176301,0.0001141354,0.00004002122,0.000004011879,0.00001262103,5.628373e-7,0.0000483559],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005010249,"threshold_uncertainty_score":0.01676095,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2634811373342701,"score_gpt":0.489166837747945,"score_spread":0.2256857004136749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}